[go: up one dir, main page]

GB201819125D0 - Biomarkers and uses thereof - Google Patents

Biomarkers and uses thereof

Info

Publication number
GB201819125D0
GB201819125D0 GBGB1819125.4A GB201819125A GB201819125D0 GB 201819125 D0 GB201819125 D0 GB 201819125D0 GB 201819125 A GB201819125 A GB 201819125A GB 201819125 D0 GB201819125 D0 GB 201819125D0
Authority
GB
United Kingdom
Prior art keywords
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1819125.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB1819125.4A priority Critical patent/GB201819125D0/en
Publication of GB201819125D0 publication Critical patent/GB201819125D0/en
Priority to PCT/GB2019/051026 priority patent/WO2020104762A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GBGB1819125.4A 2018-11-23 2018-11-23 Biomarkers and uses thereof Ceased GB201819125D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1819125.4A GB201819125D0 (en) 2018-11-23 2018-11-23 Biomarkers and uses thereof
PCT/GB2019/051026 WO2020104762A1 (en) 2018-11-23 2019-04-09 Biomarkers and uses of pnp inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1819125.4A GB201819125D0 (en) 2018-11-23 2018-11-23 Biomarkers and uses thereof

Publications (1)

Publication Number Publication Date
GB201819125D0 true GB201819125D0 (en) 2019-01-09

Family

ID=65024416

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1819125.4A Ceased GB201819125D0 (en) 2018-11-23 2018-11-23 Biomarkers and uses thereof

Country Status (2)

Country Link
GB (1) GB201819125D0 (en)
WO (1) WO2020104762A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021022105A1 (en) * 2019-07-31 2021-02-04 The Regents Of The University Of California Compositions and methods for treating cancer with nucleoside-metabolism modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002499A1 (en) * 1994-07-15 1996-02-01 Merrell Pharmaceuticals Inc. Difluorostatone antiviral agents
GB201702392D0 (en) * 2017-02-14 2017-03-29 Univ Edinburgh Methods for cancer diagnosis using a gene expression signature

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
A. BRIDGEMAN ET AL.: "Viruses transfer the antiviral second messenger cGAMP between cells", SCIENCE, vol. 349, 2015, pages 1228 - 1232, XP055289749, DOI: doi:10.1126/science.aab3632
D. MARUYAMA ET AL.: "Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma", ANN HEMATOL, 2018
D. R. HOWARD ET AL.: "Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL", LEUKEMIA, vol. 31, 2017, pages 2416 - 2425
E. ARPAIA ET AL.: "Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 191, 2000, pages 2197 - 2208
E. FRANZOLIN; C. SALATA; V. BIANCHI; C. RAMPAZZO: "The Deoxynucleoside Triphosphate Triphosphohydrolase Activity of SAMHD 1 Protein Contributes to the Mitochondrial DNA Depletion Associated with Genetic Deficiency of Deoxyguanosine Kinase", J BIOL CHEM, vol. 290, 2015, pages 25986 - 25996
J. HERTZOG ET AL.: "Infection with a Brazilian isolate of Zika virus generates RIG-I stimulatory RNA and the viral NS5 protein blocks type I IFN induction and signaling", EUR J IMMUNOL, 2018
J. REHWINKEL ET AL.: "SAMHD1-dependent retroviral control and escape in mice", THE EMBO JOURNAL, vol. 32, 2013, pages 2454 - 2462
K. BALAKRISHNAN ET AL.: "Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia", BLOOD, vol. 116, 2010, pages 886 - 892
K. BALAKRISHNAN; F. RAVANDI; S. BANTIA; A. FRANKLIN; V. GANDHI: "Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia", CLIN LYMPHOMA MYELOMA LEUK, vol. 13, 2013, pages 458 - 466
K. BALAKRISHNAN; R. NIMMANAPALLI; F. RAVANDI; M. J. KEATING; V. GANDHI: "Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells", BLOOD, vol. 108, 2006, pages 2392 - 2398
M. FEOKTISTOVA; P. GESERICK; M. LEVERKUS: "Crystal Violet Assay for Determining Viability of Cultured Cells", 2016, COLD SPRING HARB PROTOC
M. OGURA ET AL.: "Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies", CANCER SCI, vol. 103, 2012, pages 1290 - 1295
M. RENTOFT ET AL.: "Heterozygous colon cancer-associated mutations of SAMHD1 have functional significance", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 113, 2016, pages 4723 - 4728
P. JOHANSSON ET AL.: "SAMHD 1 is recurrently mutated in T-cell prolymphocytic leukemia", BLOOD CANCER J, vol. 8, no. 11, 2018
R. ALONSO ET AL.: "Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM", BLOOD, vol. 114, 2009, pages 1563 - 1575
R. CLIFFORD ET AL.: "SAMHD 1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage", BLOOD, vol. 123, 2014, pages 1021 - 1031, XP055259020, DOI: doi:10.1182/blood-2013-04-490847
R. DUMMER ET AL.: "Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sezary syndrome", ANN ONCOL, vol. 25, 2014, pages 1807 - 1812
S. BANTIA ET AL.: "Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent", INTERNATIONAL IMMUNOPHARMACOLOGY, vol. 1, 2001, pages 1199 - 1210, XP008037419, DOI: doi:10.1016/S1567-5769(01)00056-X
S. H. SWERDLOW: "WHO classification of tumours of haematopoietic and lymphoid tissues", INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, 2008
S. JIA; L. MARJAVAARA; R. BUCKLAND; S. SHARMA; A. CHABES: "Determination of deoxyribonucleoside triphosphate concentrations in yeast cells by strong anion-exchange high-performance liquid chromatography coupled with ultraviolet detection", METHODS MOL BIOL, vol. 1300, 2015, pages 113 - 121
T. MUNIR ET AL.: "Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL", LEUKEMIA, vol. 31, 2017, pages 2085 - 2093
V. GANDHI ET AL.: "A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine", BLOOD, vol. 106, 2005, pages 4253 - 4260, XP055338339, DOI: doi:10.1182/blood-2005-03-1309
V. GANDHI; K. BALAKRISHNAN: "Pharmacology and mechanism of action of forodesine, a T-cell targeted agent", SEMIN ONCOL, vol. 34, 2007, pages S8 - 12
Z. KONG ET AL.: "Simultaneous determination of ribonucleoside and deoxyribonucleoside triphosphates in biological samples by hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry", NUCLEIC ACIDS RESEARCH, vol. 46, 2018, pages e66

Also Published As

Publication number Publication date
WO2020104762A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
ZA201908301B (en) Biomarkers and uses thereof
IL279458A (en) Neoantigens and uses thereof
IL275826A (en) Anti-mct1 antibodies and uses thereof
IL277502A (en) Compounds and uses thereof
SG11202008579UA (en) Anti-phf-tau antibodies and uses thereof
GB201703058D0 (en) Biomarkers
IL283875A (en) Anti-il-27 antibodies and uses thereof
GB201812561D0 (en) Biomarkers and uses thereof
IL287503A (en) Thiosemicarbazates and uses thereof
SG11202007495SA (en) Bcma-binding antibodies and uses thereof
IL279483A (en) Cyanotriazole compounds and uses thereof
SG11202103849TA (en) Anti-periostin antibodies and uses thereof
GB201806042D0 (en) Biomarkers and uses thereof
GB201609951D0 (en) Biomarkers signatures and uses thereof
GB201801102D0 (en) New compounds and uses
GB201703123D0 (en) Biomarkers
GB201609950D0 (en) Biomarkers signatures and uses thereof
IL280369A (en) New myokines and uses thereof
GB201819125D0 (en) Biomarkers and uses thereof
GB201708741D0 (en) Biomarkers and uses thereof
GB201806349D0 (en) New compounds and uses
GB201904555D0 (en) Biomarkers and uses thereof
IL278919A (en) Combinations comprising tropifexor and cenicriviroc
GB201719565D0 (en) Biomarker and uses thereof
HK40027100A (en) Biomarkers and uses thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)